stockrow
Saturday 7 November 2026
Export RANI’s income statement to Excel — free account
Rani Therapeutics Holdings, Inc.
RANI Healthcare Biotechnology
Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +77.8%
- Free cash flow
- −55.3%
Quarter to June 2026, against a year earlier
0.54
0.02
+3.85%
Follow RANI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
28.17 | 39.33 | 24.84 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(15.76) | (20.22) | 303.69 | — | |
P/B ratio |
2.96 | 3.70 | 2.15 | — | |
Price to Tangible BV |
2.96 | 3.70 | 2.15 | — | |
EV/Sales |
20.72 | 31.06 | 15.40 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(5.16) | (6.08) | (2.96) | — | |
EV/FCF |
(5.14) | (6.06) | (2.94) | — | |
Quick Ratio |
5.21 | 3.28 | 4.08 | 0.22 | |
Current Ratio |
5.31 | 3.40 | 4.21 | 0.26 | |
Net Debt/EBITDA |
5.97 | 5.15 | 5.89 | (1.35) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 133.51% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | (1.13) | |
Asset Turnover |
0.13 | 0.09 | 0.08 | 0.00 | |
Operating CF/Net income |
1.22 | 0.92 | (0.03) | 0.94 | |
Capex/Depreciation |
0.28 | 0.18 | 0.00 | 0.00 | |
Interest Coverage |
(1,103.50) | (94.76) | (24.67) | (10.01) | |
Research and Development Expense of Revenue |
293.74% | 302.17% | 336.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
323.13% | 286.07% | 348.19% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
141.92% | 122.01% | 153.18% | 0.00% | |
Graham Net Nets |
0.31 | 0.23 | 0.41 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(35.53%) | (56.16%) | (43.70%) | — | |
Free Cash Flow Yield |
(14.30%) | (13.02%) | (21.06%) | — | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.00 | |
Operating CF per Share |
(0.05) | (0.04) | 0.00 | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | 0.00 | (0.11) | |
Cash per Share |
0.29 | 0.24 | 0.75 | 0.09 | |
Shareholders Equity per Share |
0.26 | 0.20 | 0.63 | (0.26) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.26 | 0.20 | 0.63 | (0.26) | |
Free Cash Flow |
(9.06) | (6.51) | 0.29 | (5.06) | |
Working Capital |
45.89 | 33.24 | 40.65 | (14.19) | |
Capital Expenditures |
(0.03) | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
43.67 | 30.76 | 36.21 | (17.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
2.37 | 1.12 | 1.08 | — | |
Average Payables |
1.42 | 1.19 | 0.83 | 2.02 | |
Average Assets |
38.87 | 38.00 | 47.63 | 26.84 | |
Average Common Equity |
19.42 | 15.10 | 22.50 | (3.10) |
Columns are period end dates